Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Matt Posard

Premium

Matt Posard has joined the board of directors of Halozyme Therapeutics, a biopharmaceutical company. Posard is currently Illumina's senior vice president and general manager of translational and consumer genomics. He has worked for the San Diego-based array vendor since 2006, serving first as its vice president of global marketing and then later as vice president of global sales. Prior to joining Illumina, Posard held various marketing positions at Gen-Probe and Biosite.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.